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Summary 
Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds to major histocompati- 
bility complex class II molecules and selectively interacts with T  cells that bear certain T  cell 
receptor (TCR) V3 domains. Administration of SEB in adult mice results in initial proliferation 
of V38 + T cells followed by a state of unresponsiveness resulting from a combination of clonal 
deletion and clonal anergy in the SEB-reactive population.  At this time, it is unclear what rela- 
tionship exists between the T  cells that have proliferated and those that  have been deleted or 
have become anergic.  Here we show that  only a fraction of the potentially reactive V38 + T 
cells proliferate in response to SEB in vivo, and that all the cells that have proliferated eventually 
undergo apoptosis. Virtually no apoptosis can be detected in the nonproliferating V38 + T cells. 
These data demonstrate  a causal relationship  between proliferation  and apoptosis in response 
to SEB in vivo, and they further indicate that T  cells bearing the same TCR. V~ segment can 
respond differently to the same superantigen. The implications of this differential responsiveness 
in  terms  of activation  and tolerance are discussed. 
S 
uperantigens are operationally defined as molecules that 
bind class II MHC and stimulate T cells that bear a given 
TCR B-chain variable region (1, 2). For instance,  staphylo- 
coccal enterotoxin  B  (SEB)  predominantly  interacts  with 
V~8 + T  cells  (3, 4).  In vivo treatment  of mice with SEB 
leads to an initial increase in the percentage of V38 + T cells 
in both the CD4 and CD8 subsets (5). Substantial numbers 
of cycling V38 + T  cells are observed at this stage (5). This 
proliferation  is  followed by a decrease in  the  numbers  of 
V38 +  cells,  eventually  reaching  lower  levels  than  those 
found  before treatment  with  SEB.  The  remaining  V~8 + 
cells are anergic since they fail to proliferate in vitro in re- 
sponse to SEB or anti-V38  mAb  (3,  4,  6). 
At this time, it is unclear what relationship exists between 
cells undergoing proliferation,  apoptosis,  or anergy in response 
to SEB. We had previously suggested two models that could 
account for the different fates of potentially SEB-reactive T 
cells  in  vivo  (7).  In  the  first  model,  all  V38 +  T  cells 
proliferate,  and depending on yet undefined (stochastic or en- 
vironmental)  factors,  they may progress to either apoptosis 
or anergy. In the second model, only T cells that react strongly 
to SEB undergo clonal expansion, which inevitably leads to 
cell death.  In contrast,  weakly SEB-reactive V38 + T  cells 
do not receive a strong enough signal to undergo prolifera- 
tion  and death.  Rather,  they become anergic. 
To discriminate between these two possibilities,  we studied 
the response to SEB in Vf18.2 TCR transgenic mice that had 
been exposed to the thymidine analogue bromodeoxyuridine 
(BrdU).  We find that  only a fraction of V~8 + T  cells in- 
corporate BrdU in response to SEB in vivo. All T  cells that 
incorporated BrdU eventually undergo apoptosis,  whereas vir- 
tually no apoptosis could be detected in VB8 § cells that did 
not proliferate.  Similar results were observed in both the CD4 
and  CD8  subsets.  The  remaining  V~8 +  cells,  which  we 
have shown previously to be anergic in these transgenic mice 
(8), were exclusively BrdU negative, indicating that they did 
not undergo clonal expansion.  These data directly demon- 
strate a lineage relationship between proliferating and apop- 
totic T  cells  that  respond  to SEB in vivo. 
Materials and Methods 
Animals and Treatments.  8-10-wk-old BALB/c mice were ob- 
tained from Harlan Olac (Bicester, UK). The TCK V/38.2 trans- 
genic mouse line (C57BL6.Transgenic93/lbm spf) (9) was kindly 
provided by Dr H. Bluethmann  (Hoffmann-La Roche AG, Basel, 
Switzerland). These mice were back-crossed at least five times onto 
the BALB/c background.  SEB (10 #g) from Toxin Technology 
(Saratoga, FL) was injected into each of the hind footpads. BrdU 
(Sigma Immunochemicals, St. Louis, MO) was added at 1 rag/m1 
to drinking water that contained 5% glucose 3 d before treatment 
with SEB and was changed every 3 d throughout the experiment. 
Antibodies.  The following directly labeled mAbs were used: 
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Alto, CA), anti-CD8-PE (Boehringer Mannheim GmbH, Mann- 
heim, Germany), anti-V/~8 (F23.1) (10) was directly  coupled to FITC 
in our laboratory. 
FACS  TM Sorting.  Draining LN cells were stained with the rele- 
vant antibodies and sorted using a Becton Dickinson FACStar Plus  TM 
(Becton Dickinson & Co., Mountain View, CA). Sorted cells were 
then incubated at 37~  for 1 h (to allow apoptosis to occur [3, 
4]) before further manipulation. 
Staining and Flow Cytometry.  Simultaneous staining for BrdU 
incorporation and DNA content was performed on sorted CD4 ~ 
or CD8 + LN cells as described (11). Briefly, cells were fixed in 
70% ethanol for at least 30 min and the DNA was partially dena- 
tured in 3 N  HC1, then neutralized with 0.1 M Na2B4OT. The 
cells were subsequently  stained with  FITC-coupled  anti-BrdU, 
resuspended in 100 #1 PBS containing  2.5%  FCS, and added to 
200 #1 PBS/FCS containing 3/~g/ml propidium iodide (PI), 50 
#g/ml KNAse A (Sigma), 50 mM Tris base, 50 mM NaC1, and 
5 mM EDTA, pH 7.5. Cells were then incubated 5 min at 37~ 
and analyzed on a FACScan  TM equipped with a doublet discrimina- 
tion  module. 
Results and Discussion 
To confirm that the increase in V/38 + cells observed after 
injection of SEB is a consequence of proliferation rather than 
selective migration,  we  evaluated BrdU  incorporation in 
CD4 + or CD8 + cells that were isolated from the draining 
LN  of VB8.2  TCR  transgenic  mice that  were fed BrdU 
starting 3 d before superantigen administration. More than 
99% ofT cells in these mice bear the transgenic TCR/3 chain 
(data not shown and reference 12). Fig.  1 shows that there 
is an increase in the percentage of BrdU-labeled CD4 § and 
CD8 + cells as soon as 2 d after immunization, peaking at 
around day 7,  then dropping to background levels by day 
14. CD8 § cells had a reproducibly higher BrdU incorpora- 
tion rate, especially  early during the response (day 2).  This 
difference may be  caused  by  the  faster  doubling  time  of 
CD8 + cells compared to CD4 + cells,  as observed in vitro 
(13). Alternatively, more CD8 +V~8 § T cells may have ini- 
tially responded to SEB than CD4+V/38 + T  cells. 
It is of interest that only a fraction (50-60%) of the poten- 
tially reactive VB8 + cells incorporated BrdU (Fig.  1), sug- 
gesting that although they bear the same TCR B chain, T 
cells respond differentially to SEB. This differential response 
to SEB was not restricted to V/38.2  TCR transgenic mice 
since a similar fraction of V~8 § T cells (52%) incorporated 
BrdU at  the peak of the SEB response (day 7)  in  normal 
BALB/c mice (data not shown).  It could be argued that a 
higher proportion of V/38 + T  cells would incorporate BrdU 
with a higher dose of SEB. Although this is formally pos- 
sible,  we were unable to increase  the dose of superantigen 
beyond 20/xg in our VBS.2 +  transgenic mice because of 
high mortality. It has been previously shown that SEB can 
induce T  cell-mediated weight loss in mice (14).  This tox- 
icity is mediated by T cell cytokines such as TNF (15). SEB 
can even be lethal when injected into BALB/c mice in com- 
bination with agents that increase the animal's susceptibility 
to hyperacute cytokine release syndrome, such as the gluco- 
corticoid receptor antagonist RU-38486 (15) or the amino- 
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Figure  1.  BrdU  incorporation  by V~8 + T cells in response to SEB in 
vivo. VB8.2 TCR. transgenic mice were fed BrdU continuously  and the 
incorporation of the nucleotide  analogue was determined in sorted LN 
CD4+ and CD8 § T cells by flow cytometry  at the indicated time points 
following SEB injection. Time 0 d indicates mice that were fed BrdU for 
at least 7 d but did not receive  SEB. One of two comparable  experiments 
is shown here. 
sugar GaIN (16). The fact that SEB, alone and at doses that 
were not lethal to nontransgenic littermates, was able to cause 
death in our V38.2 + transgenic mice is likely to be caused 
by the higher numbers of SEB-reactive,  potentially cytokine- 
secreting cells  generated in these mice. 
Since virtually all BrdU-labeled cells from our SEB-treated 
VBS.2 transgenic mice disappeared by 2 wk after immuniza- 
tion, and since some V/38 + T  cells have been shown to die 
by apoptosis in vitro in response to SEB in normal mice (3, 
4), we asked whether selective apoptosis of proliferating T 
cells could account for our observations. To address this issue, 
CD4 +  or  CD8 +  cells  were  sorted  from  LN  of BrdU- 
treated, SEB-injected V/38.2 transgenic mice and were double 
stained with anti-BrdU mAb and the DNA-binding dye PI 
(Fig. 2). 2 d after immunization with SEB, a fraction of the 
T  cells was  in cell cycle, and as expected, this fraction was 
almost exclusively in the BrdU § population. In contrast, no 
cycling cells were detected 7 d after SEB administration; how- 
ever, subdiploid (apoptotic) cells with low PI staining were 
clearly visible at this time point.  Importantly, virtually all 
subdiploid cells were found in the BrdU + population. 
This observation was extended when PI uptake was evalu- 
ated on sorted CD4 * or CD8 + cells that were electronically 
gated based on BrdU staining (Fig.  3). Subdiploid BrdU + 
cells first appeared on day 4 and increased in number to reach 
their maximum levels at around day 10,  after which time 
they were lost (presumably cleared by scavenger cells). There 
were  no  striking  differences between  the  CD4  and  CD8 
subsets,  except possibly a faster initial rate of cell death in 
the CD8 compartment. Because of the extremely low per- 
centage of BrdU + cells recovered from mice that did not re- 
ceive SEB or from mice that were analyzed 14 d after treat- 
ment with SEB (Fig. 1), no estimate for subdiploid cell content 
in these populations could be obtained. 
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content and BrdU uptake in SEB- 
reactive T cells. BrdU labeling and 
SEB injections were carried out as 
described  in  Materials  and 
Methods.  CD4 +  and  CD8 §  T 
cells  were  sorted  from  LN  of 
Vf18.2 TCR transgenic mice and 
subjected to double staining with 
anti-BrdU  mAb and PI.  Shown 
here  are  representative  contour 
plots of sorted cells for 2 and 7 d 
after injection with  SEB. 
This work shows for the first time that in a superantigen 
response, previous proliferation is a prerequisite for T cell de- 
letion in vivo. A previous study (15) demonstrated that BrdU 
could be detected in fragmented DNA from T  cell popula- 
tions recovered from SEB-injected,  BrdU-treated mice. How- 
ever, no quantitative analysis at the single cell level was car- 
ried out. These findings are consistent with in vitro studies 
showing that mature T cells in the G1 phase of the cell cycle 
are refractory to receptor-induced apoptosis,  whereas T cells 
that have progressed to the S phase are susceptible (17). In 
this context, it is not surprising that growth factors that drive 
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Figure  3.  Kinetics of appearance  of apoptotic cells in sorted CD4 + and 
CD8 + populations from BrdU-fed VflS.2 TCIL transgenic mice after SEB 
injection.  Curves represent  the percentage subdiploid  cells  in electroni- 
cally gated BrdU-positive or -negative populations.  Because of the extremely 
low percentage of BrdU + cells on day 14 (see Fig. 1), no estimate for sub- 
diploid cell content  could be obtained. 
T  cells into cycle (such as IL-2) promote apoptotic death of 
T  cells after their subsequent activation by SEB (18),  high 
doses of antigen (19),  or TCR ligation  (20,  21). 
Why do certain V/38 + T  cells proliferate and die as a re- 
sult  of contact with  SEB  in  vivo  whereas others become 
anergic? One possible  explanation may relate to differential 
affinity of TCR-superantigen interactions, depending on usage 
of TCR Vex chains.  Indeed, we and others have previously 
shown a skewing in TCR Vex usage among superantigen- 
reactive T cells (22-24), and two recent reports suggest that 
this bias may reflect a requirement for efficient TCR-MHC 
class II interactions during superantigen activation (25,  26). 
Alternatively, given that a fraction of peripheral T  cells in 
normal mice that bear activation markers such as low surface 
levels of CD45RB are refractory to further stimulation with 
superantigens (27)  and that specific antigen-primed T  cells 
are resistant to superantigen-induced cell death (28), it is con- 
ceivable that at least some of the V38 § T cells that did not 
incorporate BrdU in response to SEB in normal mice cor- 
respond to cells that had been previously activated by environ- 
mental antigens. Finally, it is possible that the anergic T cells 
are those that interacted with SEB on the surface of non- 
professional APC  (those lacking costimulatory signals). 
The mechanism that underlies SEB-induced apoptosis of 
V/38 § cells in vivo remains to be clarified.  In vitro activa- 
tion of T  cells or T  cell clones with anti-CD3 mAbs, Con 
A, or PMA plus ionomycin  leads to the induction of Fas-ligand 
expression (29, 30), which is a prerequisite for Fas-mediated 
killing (30).  We now have evidence that both Fas and Fas- 
ligand are rapidly induced on apoptotic Vfl8 + T  cells from 
SEB-injected mice, suggesting the Fas pathway is at least partly 
responsible for the deletion of SEB-reactive  T  cells in vivo 
(Renno, T., M. Hahne, J. Tschopp,  and H. R. MacDonald, 
manuscript submitted for publication). It can be speculated 
that proliferating (BrdU +) SEB-reactive  T  cells  eventually 
upregulate  their  expression  of  Fas  and  Fas-ligand,  thus 
predisposing them to  Fas-mediated killing. 
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